[Effects of angrographolide on plasma glucose level of experiment diabetic rats and its molecular mechanism].
OBJECTIVE
To investigate the effects of angrographolide on plasma glucose level of diabetic rats and its molecular mechanism.


METHODS
The diabetic model rats were established by intraperitoneal injection of streptozotocin (65 mg/kg). Diabetic rats were treated with angrographolide for 2 weeks, then the activity of superoxide dismutase (SOD) and the content of malondialdehyde (MDA) in serum were examined and the expressions of Bcl-2 and Box gene of pancreatic cells were detected.


RESULTS
Compared with model rats, the plasma glucose levels and the serum MDA contents of the angrographolide-treated rats decreased, serum insulin and activity of SOD increased significatantly (P < 0.01). The expression of Bcl-2 was lower in the model group, while the expression was stronger in the treatment group (P < 0.05).


CONCLUSIONS
Angrographolide can inhibit the apoptosis of islet cells and depress plasma glucose level of diabetic rat model. Its mechanism may be associated with the upregulation of the expression of Bcl-2, the increase of the activity of SOD, the decrease of the production of free radicals and lipid eroxidadion.
Yang
Ping
P
Department of pharmacology, Guilin Medical College, Guilin 541004, China. yp2805795@163.com
Chen
Shen-Zhou
SZ
Xiao
Sheng-Jun
SJ
Hou
Qiao-Yan
QY
Zhou
Ying-Qiong
YQ
Feng
Mei
M
Li
Li
L
D035685:Andrographis / Q000737:chemistry*; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects*; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007150:Immunohistochemistry; D007328:Insulin / Q000097:blood; D007783:Lactones / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013311:Streptozocin / Q000008:administration & dosage; D013482:Superoxide Dismutase / Q000097:blood
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D007783:Lactones; D019253:Proto-Oncogene Proteins c-bcl-2; D008315:Malondialdehyde; D013311:Streptozocin; D013482:Superoxide Dismutase